Pricing Log in Create free account
Friday 6 November 2026 Export DNLI’s income statement to Excel — free account

Denali Therapeutics Inc.

DNLI Healthcare Biotechnology

Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.

Revenue
−94.0%
EPS
+150.3%
Free cash flow
−11.8%
Total debt
−1.89%

Quarter to September 2026, against a year earlier

20.12 0.40 +2.03%
Market cap
$3.2B
P/E
0.0×
Fwd P/E
−7.7×
Dividend yield
—
F-score
4/9
Altman Z
13.78
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Denali Therapeutics Inc. (DNLI) P/E ratio

Alert me on P/E ratio

Denali Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 215× (December 2020) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 215× —
FY2019 0.0× —
FY2018 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Dec 2023 0.0× —
Sep 2023 0.0× —
22 more quarters

Against its own ten years

Low 0.0× High 215×
Ten-year median 0.0×
Current reading's percentile 89

P/E ratio against peers

Company P/E ratio
VKTX Viking Therapeutics, Inc. compare n/m
DNLI Denali Therapeutics Inc. n/m
CELC Celcuity, Inc. compare n/m
VRDN Viridian Therapeutics, Inc. compare n/m
TARS Tarsus Pharmaceuticals, Inc. compare n/m
IDYA IDEAYA Biosciences, Inc. compare n/m
DYN Dyne Therapeutics, Inc. compare n/m
ELVN Enliven Therapeutics, Inc. compare n/m
TLX Telix Pharmaceuticals Limited compare —
Biotechnology industry median 10.3×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on DNLI